Separately, HC Wainwright reduced their price objective on Ayala Pharmaceuticals from $18.00 to $12.00 and set a buy rating for the company in a research report on Tuesday, August 16th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $12.60.
Ayala Pharmaceuticals Stock Down 10.1 %
Shares of AYLA stock opened at $1.16 on Tuesday. The business has a 50 day moving average of $1.45 and a two-hundred day moving average of $2.14. Ayala Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $14.50. The company has a market cap of $17.13 million, a P/E ratio of -0.46 and a beta of 2.25.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in Ayala Pharmaceuticals during the 2nd quarter valued at $42,000. CSS LLC IL raised its stake in Ayala Pharmaceuticals by 98.7% during the 2nd quarter. CSS LLC IL now owns 64,180 shares of the company’s stock valued at $70,000 after purchasing an additional 31,878 shares during the period. Citadel Advisors LLC acquired a new stake in Ayala Pharmaceuticals during the 2nd quarter valued at $148,000. Finally, DLD Asset Management LP raised its stake in Ayala Pharmaceuticals by 9.2% during the 1st quarter. DLD Asset Management LP now owns 172,867 shares of the company’s stock valued at $688,000 after purchasing an additional 14,635 shares during the period. Institutional investors own 28.43% of the company’s stock.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (AYLA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.